Acquired EGFR T790M Mutation in NSCLC: Testing in FFPE Tissue (OLC)

Course overview

Recent advancements for improving outcomes in NSCLC include immunotherapy treatments developed through genetic testing. EGFR mutations have been identified as a significant cause of poor response in a subset of NSCLC patients. FDA testing methods are now available using formalin-fixed paraffin embedded tissue to identify these mutations, and other genetic aberrations. The EGFR pathway, angiogenesis, tyrosine-kinase inhibitors, and in-vitro testing on FFPE tissue will be discussed.